The homeostasis of the immune system is maintained by the recirculation of naïve lymphocytes through the secondary lymphoid tissues, such as the lymph nodes, Peyer’s patches, and spleen. Upon insult by pathogens or antigens, lymphocytes become activated, and the regulated trafficking of these cells results in the integration of systemic and regional immune responses. The exquisite specificity of such lymphocyte trafficking is determined by tissue-specific guidance signals expressed by the endothelial cells of postcapillary venules, combined with counterreceptors expressed by the circulating lymphocytes. The high endothelial venules can selectively guide naïve lymphocytes into the lymph nodes and Peyer’s patches by expressing a unique combination of vascular addressins, lymphocyte-specific chemokines, and chemokine-binding molecules. The inflamed postcapillary venules in extralymphoid tissues, such as the skin and intestinal lamina propria, also use a distinct array of endothelial adhesion molecules and tissue- selective chemokines, and support the recruitment of effector and memory lymphocytes that express the appropriate receptors for tissue-specific trafficking. In this review, we summarize the present understanding of the homeostatic recirculation of naïve lymphocytes through the secondary lymphoid tissues and the specific targeting of antigen-experienced lymphocytes into the effector sites. We also revisit some previous studies that reported apparently conflicting observations.

Keywords:
Lymphoid tissues, secondary, High endothelial venules, Adhesion molecules, Chemokines, Chemokine-binding molecules
1.
Kraal G, Mebius RE: High endothelial venules: Lymphocyte traffic control and controlled traffic. Adv Immunol 1997;65:347–395.
2.
Imhof BA, Dunon D: Leukocyte migration and adhesion. Adv Immunol 1995;58:345–416.
3.
Butcher EC, Williams M, Youngman K, Rott L, Briskin M: Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209–253.
4.
von Andrian UH, Mempel TR: Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3:867–878.
5.
Miyasaka M, Tanaka T: Lymphocyte trafficking across high endothelial venules: Dogmas and enigmas. Nat Rev Immunol 2004;4:360–370.
6.
Butcher EC, Picker LJ: Lymphocyte homing and homeostasis. Science 1996;272:60–66.
7.
Westermann J, Pabst R: How organ-specific is the migration of ‘naïve’ and ‘memory’ T cells? Immunol Today 1996;17:278–282.
8.
Gowans JL: The lymphocyte – A disgraceful gap in medical knowledge. Immunol Today 1996;17:288–291.
9.
Girard JP, Springer TA: High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration. Immunol Today 1995;16:449–457.
10.
Hay JB, Hobbs BB: The flow of blood to lymph nodes and its relation to lymphocyte traffic and the immune response. J Exp Med 1977;145:31–44.
11.
Xu B, Wagner N, Pham LN, Magno V, Shan Z, Butcher EC, Michie SA: Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, α4β1 integrin/VCAM-1, and LFA-1 adhesion pathways. J Exp Med 2003;197:1255–1267.
12.
Csencsits KL, Jutila MA, Pascual DW: Nasal-associated lymphoid tissue: Phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site. J Immunol 1999;163:1382–1389.
13.
Streeter PR, Berg EL, Rouse BTN, Bargatze RF, Butcher EC: A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 1988;331:41–46.
14.
Nakache M, Berg EL, Streeter PR, Butcher EC: The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature 1989;337:179–181.
15.
Baekkevold ES, Jahnsen FL, Johansen FE, Bakke O, Gaudernack G, Brandtzaeg P, Haraldsen G: Culture characterization of differentiated high endothelial venule cells from human tonsils. Lab Invest 1999;79:327–336.
16.
Girard JP, Springer TA: Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 1995;2:113–123.
17.
Izawa D, Tanaka T, Saito K, Ogihara H, Usui T, Kawamoto S, Matsubara K, Okubo K, Miyasaka M: Expression profile of active genes in mouse lymph node high endothelial cells. Int Immunol 1999;11:1989–1998.
18.
Saito K, Tanaka T, Kanda H, Ebisuno Y, Izawa D, Kawamoto S, Okubo K, Miyasaka M: Gene expression profiling of mucosal addressin cell adhesion molecule-1+ high endothelial venule cells (HEV) and identification of a leucine-rich HEV glycoprotein as a HEV marker. J Immunol 2002;168:1050–1059.
19.
Springer TA: Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995;57:827–872.
20.
Warnock RA, Askari S, Butcher EC, von Andrian UH: Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J Exp Med 1998;187:205–216.
21.
Bargatze RF, Jutila MA, Butcher EC: Distinct roles of L-selectin and integrins α4β7 and LFA-1 in lymphocyte homing to Peyer’s patch-HEV in situ: The multistep model confirmed and refined. Immunity 1995;3:99–108.
22.
Laudanna C, Kim JY, Constantin G, Butcher E: Leukocyte integrin activation by chemokines. Immunol Rev 2002;186:37–46.
23.
Ley K: Arrest chemokines. Microcirculation 2003;10:289–295.
24.
Berlin-Rufenach C, Otto F, Mathies M, Westermann J, Owen MJ, Hamann A, Hogg N: Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J Exp Med 1999;189:1467–1478.
25.
Rosen SD: Endothelial ligands for L-selectin: From lymphocyte recirculation to allograft rejection. Am J Pathol 1999;155:1013–1020.
26.
Vestweber D, Blanks JE: Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999;79:181–213.
27.
Lowe JB: Glycosylation in the control of selectin counter-receptor structure and function. Immunol Rev 2002;186:19–36.
28.
Lasky LA, Singer MS, Dowbenko D, Imai Y, Henzel WJ, Grimley C, Fennie C, Gillett N, Watson SR, Rosen SD: An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell 1992;69:927–938.
29.
Baumhueter S, Singer MS, Henzel W, Hemmerich S, Renz M, Rosen SD, Lasky LA: Binding of L-selectin to the vascular sialomucin CD34. Science 1993;262:436–438.
30.
Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD: Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: Parallels to CD34. J Exp Med 1998;187:1965–1975.
31.
Hemmerich S, Butcher EC, Rosen SD: Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody. J Exp Med 1994;180:2219–2226.
32.
Berg EL, McEvoy LM, Berlin C, Bargatze RF, Butcher EC: L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 1993;366:695–698.
33.
Kansas GS: Selectins and their ligands: Current concepts and controversies. Blood 1996;88:3259–3287.
34.
Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM: Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 2001;194:13–27.
35.
Samulowitz U, Kuhn A, Brachtendorf G, Nawroth R, Braun A, Bankfalvi A, Bocker W, Vestweber D: Human endomucin: Distribution pattern, expression on high endothelial venules, and decoration with the MECA-79 epitope. Am J Pathol 2002;160:1669–1681.
36.
Sassetti C, Van Zante A, Rosen SD: Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem 2000;275:9001–9010.
37.
Fieger CB, Sassetti CM, Rosen SD: Endoglycan, a member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x. J Biol Chem 2003;278:27390–27398.
38.
Homeister JW, Thall AD, Petryniak B, Maly P, Rogers CE, Smith PL, Kelly RJ, Gersten KM, Askari SW, Cheng G, Smithson G, Marks RM, Misra AK, Hindsgaul O, von Andrian UH, Lowe JB: The α(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity 2001;15:115–126.
39.
Maly P, Thall A, Petryniak B, Rogers CE, Smith PL, Marks RM, Kelly RJ, Gersten KM, Cheng G, Saunders TL, Camper SA, Camphausen RT, Sullivan FX, Isogai Y, Hindsgaul O, von Andrian UH, Lowe JB: The α(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 1996;86:643–653.
40.
Hemmerich S, Bistrup A, Singer MS, van Zante A, Lee JK, Tsay D, Peters M, Carminati JL, Brennan TJ, Carver-Moore K, Leviten M, Fuentes ME, Ruddle NH, Rosen SD: Sulfation of L-selectin ligands by an HEV-restricted sulfotransferase regulates lymphocyte homing to lymph nodes. Immunity 2001;15:237–247.
41.
Yeh JC, Hiraoka N, Petryniak B, Nakayama J, Ellies LG, Rabuka D, Hindsgaul O, Marth JD, Lowe JB, Fukuda M: Novel sulfated lymphocyte homing receptors and their control by a Core1 extension α1,3-N-acetylglucosaminyltransferase. Cell 2001;105:957–969.
42.
van Zante A, Gauguet JM, Bistrup A, Tsay D, von Andrian UH, Rosen SD: Lymphocyte-HEV interactions in lymph nodes of a sulfotransferase-deficient mouse. J Exp Med 2003;198:1289–1300.
43.
M’Rini C, Cheng G, Schweitzer C, Cavanagh LL, Palframan RT, Mempel TR, Warnock RA, Lowe JB, Quackenbush EJ, von Andrian UH: A novel endothelial L-selectin ligand activity in lymph node medulla that is regulated by α(1,3)-fucosyltransferase-IV. J Exp Med 2003;198:1301–1312.
44.
Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT: A chemokine expressed lymphoid high endothelial venules promotes the adhesion and chemotaxis of naïve T lymphocytes. Proc Natl Acad Sci USA 1998;95:258–263.
45.
Stein JV, Rot A, Luo Y, Narasimhaswamy M, Nakano H, Gunn MD, Matsuzawa A, Quackenbush EJ, Dorf ME, von Andrian UH: The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J Exp Med 2000;191:61–76.
46.
Warnock RA, Campbell JJ, Dorf ME, Matsuzawa A, McEvoy LM, Butcher EC: The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer’s patch high endothelial venules. J Exp Med 2000;191:77–88.
47.
Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinhold FP, von Andrian UH, Brandtzaeg P, Haraldsen G: The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med 2001;193:1105–1111.
48.
Nakano H, Tamura T, Yoshimoto T, Yagita H, Miyasaka M, Butcher EC, Nariuchi H, Kakiuchi T, Matsuzawa A: Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur J Immunol 1997;27:215–221.
49.
Vassileva G, Soto H, Zlotnik A, Nakano H, Kakiuchi Hedrick JA, Lira S: The reduced expression of 6Ckine in the plt mouse results from the deletion of one of two 6Ckine genes. J Exp Med 1999;190:1183–1188.
50.
Nakano H, Gunn MD: Gene duplications at the chemokine locus on mouse chromosome 4:Multiple strain-specific haplotypes and the deletion of secondary lymphoid-organ chemokine and EBI-1 ligand chemokine genes in the plt mutation. J Immunol 2001;66:361–369.
51.
Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC: Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998;279:381–384.
52.
Tangemann K, Gunn MD, Giblin P, Rosen SD: A high-endothelial cell derived chemokine induces rapid, efficient, and subset-specific arrest of rolling T lymphocytes on a reconstituted endothelial substrate. J Immunol 1998;161:6330–6337.
53.
Pachynski RK, Wu SW, Gunn MD, Erle DJ: Secondary lymphoid-tissue chemokine (SLC) stimulates integrin α4β7-mediated adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under flow. J Immunol 1998;161:952–956.
54.
Okada T, Ngo VN, Ekland EH, Forster R, Lipp M, Littman DR, Cyster JG: Chemokine requirements for B cell entry to lymph nodes and Peyer’s patches. J Exp Med 2002;196:65–75.
55.
Bowman EP, Campbell JJ, Soler D, Dong Z, Manlongat N, Picarella D, Hardy RR, Butcher EC: Developmental switches in chemokine response profiles during B cell differentiation and maturation. J Exp Med 2000;191:1303–1318.
56.
Ebisuno Y, Tanaka T, Kanemitsu N, Kanda H, Yamaguchi K, Kaisho T, Akira S, Miyasaka M: Cutting edge: The B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer’s patches and affects B cell trafficking across high endothelial venules. J Immunol 2003;171:1642–1646.
57.
Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA: Leukocyte extravasation: Chemokine transport and presentation by the endothelium. Blood 2002;100:3853–3860.
58.
Kashiwazaki M, Tanaka T, Kanda H, Ebisuno Y, Izawa D, Fukuma N, Akimitsu N, Sekimizu K, Monden M, Miyasaka M: A high endothelial venule-expressing promiscuous chemokine receptor DARC can bind inflammatory, but not lymphoid, chemokines and is dispensable for lymphocyte homing under physiological conditions. Int Immunol 2003;15:1219–1227.
59.
Neote K, Mak JY, Kolakowski LF Jr, Schall TJ: Functional and biochemical analysis of the cloned Duffy antigen: Identity with the red blood cell chemokine receptor. Blood 1994;84:44–52.
60.
Hadley TJ, Peiper C: From malaria to chemokine receptor: The emerging physiologic role of the Duffy blood group antigen. Blood 1997;89:3077–3091.
61.
Hwa V, Oh Y, Rosenfeld RG: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999;20:761–787.
62.
Usui T, Murai T, Tanaka T, Yamaguchi K, Nagakubo D, Lee CM, Kiyomi M, Tamura S, Matsuzawa Y, Miyasaka M: Characterization of mac25/angiomodulin expression by high endothelial venule cells in lymphoid tissues and its identification as an inducible marker for activated endothelial cells. Int Immunol 2002;14:1273–1282.
63.
Girard J-P, Baekkevold ES, Yamanaka T, Haraldsen G, Brandtzaeg P, Amalric F: Heterogeneity of endothelial cells. The specialized phenotype of human high endothelial venules characterized by suppression subtractive hybridization. Am J Pathol 1999;155:2043–2055.
64.
Nagakubo D, Murai T, Tanaka T, Usui T, Matsumoto M, Sekiguchi K, Miyasaka M: A high endothelial venule secretory protein, mac25/angiomodulin, interacts with multiple high endothelial venule-associated molecules including chemokines. J Immunol 2003;171:553–561.
65.
Pelletier AJ, van der Laan LJ.W, Hildbrand P, Siani MA, Thompson DA, Dawson PE, Torbett BE, Salomon DR: Presentation of chemokine SDF-1α by fibronectin mediates directed migration of T cells. Blood 2000;96:2682–2690.
66.
Anderson AO, Shaw S: T cell adhesion to endothelium: The FRC conduit system and other anatomic and molecular features which facilitate the adhesion cascade in lymph node. Semin Immunol 1993;5:271–282.
67.
Johnson-Leger C, Aurrand-Lions M, Imhof BA: The parting of the endothelium: Miracle, or simply a junctional affair? J Cell Sci 2000;113:921–933.
68.
Cinamon G, Shinder V, Alon R: Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001;2:515–522.
69.
Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA: Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 2003;421:748–753.
70.
Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA: CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002;3:143–150.
71.
Aurrand-Lions M, Duncan L, Ballestrem C, Imhof BA: JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells. J Biol Chem 2001;276:2733–2741.
72.
Aurrand-Lions M, Johnson-Leger C, Wong C, Du Pasquier L, Imhof BA: Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members. Blood 2001;98:3699–3707.
73.
Johnson-Leger CA, Aurrand-Lions M, Beltraminelli N, Fasel N, Imhof BA: Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration. Blood 2002;100:2479–2486.
74.
Miller MJ, Wei SH, Cahalan MD, Parker I: Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy. Proc Natl Acad Sci USA 2003;100:2604–2609.
75.
Mempel TR, Henrickson SE, von Andrian UH: T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154–159.
76.
Gretz JE, Kaldjian E, Anderson AO, Shaw S: Sophisticated strategies for information encounter in the lymph node: The reticular network as a conduit of soluble information and a highway for cell traffic. J Immunol 1996;157:495–499.
77.
Gretz JE, Anderson AO, Shaw S: Cords, channels, corridors and conduits: Critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol Rev 1997;156:11–24.
78.
Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S: Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med 2000;192:1425–1440.
79.
Palframan R, Jung S, Cheng G, Weninger W, Luo Y, Dorf M, Littman DR, Rollins BJ, Zweerink H, Rot A, von Andrian UH: Inflammatory chemokine transport and presentation in HEV: A remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med 2001;194:1361–1373.
80.
Janatpour MJ, Hudak S, Sathe M, Sedgwick JD, McEvoy LM: Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J Exp Med 2001;194:1375–1384.
81.
Pabst R: The spleen in lymphocyte migration. Immunol Today 1988;9:43–45.
82.
Lo CG, Lu TT, Cyster JG: Integrin-dependence of lymphocyte entry into the splenic white pulp. J Exp Med 2003;197:353–361.
83.
Nolte MA, Hamann A, Kraal G, Mebius RE: The strict regulation of lymphocyte migration to splenic white pulp does not involve common homing receptors. Immunology 2002;106:299–307.
84.
Kraal G, Schornagel K, Streeter PR, Holzmann B, Butcher EC: Expression of the mucosal vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen. Am J Pathol 1995;147:763–771.
85.
Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A, Hamann A: P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 1997;385:81–83.
86.
Hirata T, Merrill-Skoloff G, Aab M, Yang J, Furie BC, Furie B: P-Selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration. J Exp Med 2000;192:1669–1676.
87.
Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS: Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978–981.
88.
Takahashi R, Mizukawa Y, Yamazaki Y, Hayakawa K, Hayakawa J, Kudo A, Shiohara T: In vitro differentiation from naive to mature E-selectin binding CD4 T cells: Acquisition of skin-homing properties occurs independently of cutaneous lymphocyte antigen expression. J Immunol 2003;171:5769–5777.
89.
Kunkel EJ, Butcher EC: Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002;16:1–4.
90.
Campbell DJ, Kim CH, Butcher EC: Chemokines in the systemic organization of immunity. Immunol Rev 2003;195:58–71.
91.
Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, Andrew DP, Warnke R, Ruffing N, Kassam N, Wu L, Butcher EC: The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776–780.
92.
Hudak S, Hagen M, Liu Y, Catron D, Oldham E, McEvoy LM, Bowman EP: Immune surveillance and effector functions of CCR10+ skin homing T cells. J Immunol 2002;169:1189–1196.
93.
Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A: CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8:157–165.
94.
Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC: CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001;194:1541–1547.
95.
Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, Butcher EC, Andrew DP, Agace WW: Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000;192:761–768.
96.
Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD, Andrew DP, Targan SR: The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000;165:5069–5076.
97.
Kunkel EJ, Butcher EC: Plasma-cell homing. Nat Rev Immunol 2003;3:822–829.
98.
Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soler D: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol 2000;165:2943–2949.
99.
Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, Bowman EP, Butcher EC: CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 2003;111:1001–1010.
100.
Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC: A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasma blasts. J Immunol 2003;170:3799–3805.
101.
Campbell DJ, Butcher EC: Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002;195:135–141.
102.
Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH: Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 2003;424:88–93.
103.
Zlotnik A, Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121–127.
104.
Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, Butcher EC: Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001;108:1331–1339.
105.
Nanki T, Lipsky PE: Lack of correlation between chemokine receptor and Th1/Th2 cytokine expression by individual memory T cells. Int Immunol 2000;12:1659–1667.
106.
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708–712.
107.
Unsoeld H, Krautwald S, Voehringer D, Kunzendorf U, Pircher H: Cutting edge: CCR7+ and CCR7– memory T cells do not differ in immediate effector cell function. J Immunol 2002;169:638–641.
108.
Debes GF, Hopken UE, Hamann A: In vivo differentiated cytokine-producing CD4+ T cells express functional CCR7. J Immunol 2002;168:5441–5447.
109.
Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH: Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4:965–973.
110.
Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ: Mast-cell dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003;4:974–981.
111.
Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, Carafone AD, Gerszten RE, Luster AD: Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003;4:982–990.
112.
Hall JG, Morris B: The immediate effect of antigens on the cell output of a lymph node. Br J Exp Pathol 1965;46:450–454.
113.
Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037–5044.
114.
Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346–349.
115.
Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355–360.
116.
Luo ZJ, Tanaka T, Kimura F, Miyasaka M: Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Immunopharmacology 1999;41:199–207.
117.
Sprent J: Circulating T and B lymphocytes of the mouse. I. Migratory properties. Cell Immunol 1973;7:10–39.
118.
Stevens SK, Weissman IL, Butcher EC: Differences in the migration of B and T lymphocytes: Organ-selective localization in vivo and the role of lymphocyte-endothelial cell recognition. J Immunol 1982;128:844–851.
119.
Pellas TC, Weiss L: Migration pathways of recirculating murine B cells and CD4+ and CD8+ T lymphocytes. Am J Anat 1990;187:355–373.
120.
Tang LK, Steeber DA, Zhang X-Q, Tedder TF: Intrinsic differences in L-selectin expression levels affect T and B lymphocyte subset-specific recirculation pathways. J Immunol 1998;160:5113–5121.
121.
Westermann J, Persin S, Matyas J, van der Meide P, Pabst R: IFN-γ influences the migration of thoracic duct B and T lymphocyte subsets in vivo. Random increase in disappearance from the blood and differential decrease in reappearance in the lymph. J Immunol 1993;150:3843–3852.
122.
Westermann J, Nagahori Y, Walter S, Heerwagen C, Miyasaka M, Pabst R: B and T lymphocyte subsets enter peripheral lymph nodes and Peyer’s patches without preference in vitro: No correlation occurs between their localization in different types of high endothelial venules and the expression of CD44, VLA-4, LFA-1, ICAM-1, CD2 or L-selectin. Eur J Immunol 1994;24:2312–2316.
123.
Blaschke V, Micheel B, Pabst R, Westermann J: Lymphocyte traffic through lymph nodes and Peyer’s patches of the rat: B- and T-cell-specific migration patterns within the tissue, and their dependence on splenic tissue. Cell Tissue Res 1995;282:377–386.
124.
Walter S, Micheel B, Pabst R, Westermann J: Interaction of B and T lymphocyte subsets with high endothelial venules in the rat: Binding in vitro does not reflect homing in vivo. Eur J Immunol 1995;25:1199–1205.
125.
Nieuwenhuis P, Ford WL: Comparative migration of B- and T-lymphocytes in the rat spleen and lymph nodes. Cell Immunol 1976;23:254–267.
126.
Ford WL: Lymphocyte migration and immune responses. Prog Allergy 1975;19:1–59.
127.
Wilkinson PC: Assays of leukocyte locomotion and chemotaxis. J Immunol Methods 1998;216:139–153.
128.
Wei SH, Parker I, Miller MJ, Cahalan MD: A stochastic view of lymphocyte motility and trafficking within the lymph node. Immunol Rev 2003;195:136–159.
129.
Petrie HT: Cell migration and the control of post-natal T-cell lymphopoiesis in the thymus. Nat Rev Immunol 2003;3:859–866.
130.
Johnston B, Kim CH, Soler D, Emoto M, Butcher EC: Differential chemokine responses and homing patterns of murine TCR αβ NKT cell subsets. J Immunol 2003;171:2960–2969.
131.
Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, Debes GF, Lauber J, Frey O, Przybylski GK, Niesner U, De La Rosa M, Schmidt CA, Brauer R, Buer J, Scheffold A, Hamann A: Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004;199:303–313.
132.
Lu TT, Cyster JG: Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 2002;297:409–412.
133.
Ansel KM, Harris RB, Cyster JG: CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002;16:67–76.
134.
Pabst R, Westermann J: Lymphocyte traffic to lymphoid and non-lymphoid organs in different species is regulated by several mechanisms; in Hamann A (ed): Adhesion Molecules and Chemokines in Lymphocyte Trafficking. Amsterdam, Harwood Academic Publishers, 1997, pp 21–37.
135.
Bazzoni G: The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 2003;15:525–530.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.